CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	3 Months Ended
Mar. 31, 2022	Mar. 31, 2021
Cash flows from operating activities:
Net income	$ 19,438	$ 18,038
Adjustments to reconcile net income to net cash provided by operating activities:
(Credit) provision for credit losses	(3,195)	(821)
Depreciation and amortization of premises and equipment	1,756	1,608
Non-cash lease expense (benefit)	702	(28)
Cash flows from operating leases	(1,506)	(1,599)
Loss on disposal of fixed assets	1	32
Amortization of mortgage servicing rights	534	1,232
Net amortization and accretion of premium/discounts on investment securities	1,401	2,391
Share-based compensation expense	197	879
Net gain on sales of residential mortgage loans	(769)	(2,439)
Proceeds from sales of loans held for sale	31,372	57,439
Originations of loans held for sale	(31,749)	(43,547)
Equity in earnings of unconsolidated entities	(90)	(107)
Distributions from unconsolidated entities	66	181
Net decrease (increase) in cash surrender value of bank-owned life insurance	1,741	(898)
Deferred income taxes	(26,297)	(6,687)
Net tax benefit from share-based compensation	73	131
Net change in other assets and liabilities	15,735	(6,126)
Net cash provided by operating activities	9,410	19,679
Cash flows from investing activities:
Proceeds from maturities of and calls on investment securities available-for-sale	59,471	80,015
Purchases of investment securities available-for-sale	(66,610)	(139,785)
Net loan repayments (originations)	6,377	(138,572)
Purchases of loan portfolios	(79,713)	(36,059)
Purchases of bank-owned life insurance	0	(3,550)
Proceeds from bank-owned life insurance	0	499
Net purchases of premises, equipment and land	(858)	(8,961)
Contributions to unconsolidated entities	(495)	(2,736)
Net proceeds from (purchases) redemption of FHLB stock	(979)	82
Net cash used in investing activities	(82,807)	(249,067)
Cash flows from financing activities:
Net (decrease) increase in deposits	(40,127)	412,832
Net decrease in short-term borrowings	0	(22,000)
Cash dividends paid on common stock	(7,201)	(6,490)
Repurchases of common stock and other related costs	(6,731)	0
Net proceeds from issuance of common stock and stock option exercises	679	870
Net cash (used in) provided by financing activities	(53,380)	385,212
Net (decrease) increase in cash and cash equivalents	(126,777)	155,824
Cash and cash equivalents at beginning of period	328,907	104,067
Cash and cash equivalents at end of period	202,130	259,891
Cash paid during the period for:
Interest	1,266	1,681
Income taxes	3,283	2,445
Supplemental disclosure of non-cash information:
Net change in common stock held by directors’ deferred compensation plan	(1,114)	0
Net transfer of investment securities available-for-sale to held-to-maturity	$ 329,503	$ 0

The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets, and the amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value.

No definition available.